ArticleLung2025
Soluble Transferrin Receptor-1 in Pulmonary Hypertension Associated with COPD.
Article in Lung, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- TMPRSS11E-mediated TFR1 cleavage influences IFN-γR2 internalization and the macrophage innate response.Communications biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeThe pulmonary vascular involvement of COPD ranges from severe airway obstruction without pulmonary hypertension (PH) to mild airway obstruction with severe PH. Iron-dependent molecular regulators like hypoxia-inducible factor-2 (HIF-2) may contribute to these phenotypic variations. We explored the role of soluble transferrin receptor-1 (sTfR1) for diagnosis and prognosis of PH associated with COPD.
methodsWe analyzed COPD outpatients who underwent right heart catheterization and performed unsupervised clustering analysis based on sTfR1 levels and non-invasive clinical parameters to identify specific COPD phenotypes. Additionally, we examined explanted end-stage COPD lungs for TfR1 expression and iron deposition.
resultssTfR1 was associated with mean pulmonary artery pressure (mPAP) (r = 0.45, p < 0.001), pulmonary vascular resistance (PVR) (r = 0.395, p < 0.001) and poor survival. sTfR1 predicted severe PH (AUROC [95% CI], 0.72 [0.61-0.83]), and AUROC was further improved based on a combination of sTfR1 and low hemoglobin (0.82 [0.73-0.92]). sTfR1-based cluster analysis distinguished three COPD phenotypes with significantly different survival. One of the two clusters with poor survival was characterized by moderate airway obstruction and moderate PH but elevated sTfR1, anemia and inflammation. In explanted COPD lungs, TfR1-positive and iron-laden cells, most likely, consisted of macrophages, and iron-loaded cell density was negatively correlated with mPAP in patients with moderate/severe PH (r = - 0.681, p = 0.015).
conclusionsElevated sTfR1 predicts poor prognosis in patients with COPD and, particularly in combination with low hemoglobin, may serve as a biomarker for severe PH in COPD, identifying a distinct phenotype with systemic inflammation, anemia and iron deficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.